<p>Cullen Investment Group LTD. 在最近向证券交易委员会（SEC）提交的 13F 表格中披露，第四季度将其在爱德华生命科学公司（NYSE:EW - 免费报告）的股份减少了 60.7%。该机构投资者在出售了 13,494 股后，持有该医疗研究公司 8,740 股股票。截至其最近的 SEC 文件，Cullen Investment Group LTD. 在爱德华生命科学的持股价值为 744,000 美元。</p>
<p>获取 <strong>爱德华生命科学</strong> 的提醒：</p>
<ul>
<li>深入分析医疗行业收益：AZN vs. EW vs. ZBH</li>
</ul>
<p>其他一些对冲基金和机构投资者最近也对该股票的持仓进行了调整。JPL Wealth Management LLC 在第三季度新购入了价值约 25,000 美元的爱德华生命科学股份。True Wealth Design LLC 在第三季度将其在爱德华生命科学的持仓增加了 251.5%。True Wealth Design LLC 目前拥有 362 股该医疗研究公司的股票，价值 28,000 美元，此前在上个季度又购买了 259 股。Hantz Financial Services Inc. 在第三季度将其在爱德华生命科学的持股增加了 76.6%。Hantz Financial Services Inc. 目前拥有 378 股该医疗研究公司的股票，价值 29,000 美元，此前在上个季度又购买了 164 股。Rakuten Securities Inc. 在第二季度将其在爱德华生命科学的持股增加了 413.7%。Rakuten Securities Inc. 目前拥有 375 股该医疗研究公司的股票，价值 29,000 美元，此前在上个季度又购买了 302 股。最后，Steigerwald Gordon &amp; Koch Inc. 在第三季度新购入了价值约 30,000 美元的爱德华生命科学股份。79.46% 的股票由机构投资者持有。</p>
<h2>爱德华生命科学股票上涨 1.2%</h2>
<p>爱德华生命科学公司（NYSE EW）周四开盘价为 82.71 美元。爱德华生命科学公司的 1 年最低价为 65.94 美元，1 年最高价为 87.89 美元。该公司的 50 日移动平均线为 82.16 美元，200 日移动平均线为 81.66 美元。公司当前比率为 3.72，速动比率为 3.09，债务与股本比率为 0.06。该公司的市值为 480.4 亿美元，市盈率为 45.20，市盈率增长比率为 2.13，贝塔值为 0.93。</p>
<ul>
<li>超越生物技术——3 只适合成长型投资者的医疗股票</li>
</ul>
<p>爱德华生命科学（NYSE:EW - 获取免费报告）最近在 2 月 10 日发布了季度财报。该医疗研究公司报告的每股收益为 0.58 美元，低于分析师一致预期的 0.62 美元，差距为 0.04 美元。爱德华生命科学的股本回报率为 14.50%，净利润率为 17.69%。该公司在本季度的收入为 15.7 亿美元，而一致预期为 15.4 亿美元。去年同期，该公司每股收益为 0.59 美元。公司的季度收入同比增长 13.3%。爱德华生命科学已将其 2026 年第一季度的指导目标设定为 0.700-0.760 每股收益。股票分析师预计爱德华生命科学公司今年将发布 2.45 每股收益。</p>
<h2>华尔街分析师观点</h2>
<p>几家券商最近对 EW 发表了评论。Truist Financial 在 2 月 11 日的报告中将爱德华生命科学的目标价设定为 89.00 美元，并给予该股票 &#34;持有&#34; 评级。高盛集团在 2 月 11 日的研究报告中重申了 &#34;买入&#34; 评级，并将爱德华生命科学的目标价下调至 95.00 美元（之前为 108.00 美元）。Weiss Ratings 在 1 月 21 日的研究报告中重新发布了爱德华生命科学的 &#34;持有 (c)&#34; 评级。Piper Sandler 在 2 月 11 日的报告中重申了 &#34;增持&#34; 评级，并将爱德华生命科学的目标价设定为 100.00 美元（之前为 98.00 美元）。最后，加拿大皇家银行在 12 月 5 日的研究报告中将爱德华生命科学的目标价从 95.00 美元上调至 100.00 美元，并给予公司 &#34;跑赢大盘&#34; 评级。三位研究分析师对该股票给予了强烈买入评级，十五位给予了买入评级，九位给予了持有评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 &#34;适度买入&#34;，平均目标价为 96.14 美元。</p>
<ul>
<li>3 只具有长期顺风的医疗行业开创者</li>
</ul>
<p><strong>获取我们最新的 EW 股票分析</strong></p>
<h2>内部交易活动</h2>
<p>在相关消息中，首席财务官 Scott B. Ullem 于 3 月 11 日出售了 13,000 股公司的股票，交易价格为 84.92 美元，总价值为 1,103,960.00 美元。出售完成后，首席财务官持有公司 39,699 股，价值约为 3,371,239.08 美元。这代表了他们持股的 24.67% 的减少。该交易已在向 SEC 提交的文件中披露，可以通过此链接访问。此外，副总裁 Daniel J. Lippis 于 3 月 11 日出售了 1,019 股股票，交易价格为 85.38 美元，总价值为 87,002.22 美元。交易完成后，副总裁直接持有公司 33,934 股，价值 2,897,284.92 美元。该交易使其持股减少了 2.92%。有关此交易的更多细节可在官方 SEC 披露中找到。内部人士在过去 90 天内共出售了价值 5,236,281 美元的 61,718 股公司股票。1.29% 的股票由公司内部人士持有。</p>
<h2>关于爱德华生命科学</h2>
<p>（免费报告）</p>
<p>爱德华生命科学是一家专注于结构性心脏病和重症监测产品及疗法的医疗科技公司。该公司设计、开发并制造用于外科手术和微创（经导管）程序的心脏瓣膜及相关输送系统。其产品组合涵盖多种瓣膜疾病，重点在于能够实现经导管主动脉瓣置换（TAVR）作为开放心脏手术替代方案的技术。</p>
<p>除了经导管心脏瓣膜——包括广为人知的 SAPIEN 系列——爱德华还提供外科组织瓣膜和心脏外科医生、介入心脏病专家及医院团队使用的辅助设备。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们认为比爱德华生命科学更好的股票</li>
</ul>
<p><strong>想看看其他对 EW 感兴趣的对冲基金持有什么吗？</strong> 请访问 HoldingsChannel.com，获取爱德华生命科学公司（NYSE:EW - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVX?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVX"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在爱德华生命科学吗？</h2>
<p>在考虑爱德华生命科学之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而爱德华生命科学并不在名单上。</p>
<p>虽然爱德华生命科学目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

HIND

纽交所高增长板生物技术指数 ETF - First Trust

标普生物技术 3 倍做多 - Direxion

<p>Cullen Investment Group LTD. 已将其在爱德华生命科学（NYSE:EW）公司的持股比例减少了 60.7%，目前持有 8,740 股，价值 744,000 美元。此变动在他们最近的 SEC 文件中有所披露。其他机构投资者也对该公司的持仓进行了调整。爱德华生命科学的股票开盘价为 82.71 美元，市值为 480.4 亿美元。该公司报告每股收益为 0.58 美元，未达到预期，但收入同比增长了 13.3%。分析师对该股票的评级不一，平均目标价为 96.14 美元</p>

<p>Cullen Investment Group LTD. reduced its stake in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 60.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,740 shares of the medical research company's stock after selling 13,494 shares during the quarter. Cullen Investment Group LTD.'s holdings in Edwards Lifesciences were worth $744,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Cullen Investment Group LTD. 在最近向证券交易委员会（SEC）提交的 13F 表格中披露，第四季度将其在爱德华生命科学公司（NYSE:EW - 免费报告）的股份减少了 60.7%。该机构投资者在出售了 13,494 股后，持有该医疗研究公司 8,740 股股票。截至其最近的 SEC 文件，Cullen Investment Group LTD. 在爱德华生命科学的持股价值为 744,000 美元。</p>
</div><p>Get <strong>Edwards Lifesciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>爱德华生命科学</strong> 的提醒：</p>
</div><ul>
<li>A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBH</li>
</ul>
<div class="lb-trans"><ul>
<li>深入分析医疗行业收益：AZN vs. EW vs. ZBH</li>
</ul>
</div><p>A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. JPL Wealth Management LLC acquired a new stake in shares of Edwards Lifesciences during the 3rd quarter worth about $25,000. True Wealth Design LLC boosted its position in Edwards Lifesciences by 251.5% in the third quarter. True Wealth Design LLC now owns 362 shares of the medical research company's stock valued at $28,000 after buying an additional 259 shares in the last quarter. Hantz Financial Services Inc. grew its stake in Edwards Lifesciences by 76.6% during the third quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company's stock worth $29,000 after buying an additional 164 shares during the last quarter. Rakuten Securities Inc. increased its holdings in shares of Edwards Lifesciences by 413.7% during the second quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company's stock worth $29,000 after buying an additional 302 shares in the last quarter. Finally, Steigerwald Gordon &amp; Koch Inc. acquired a new stake in shares of Edwards Lifesciences during the third quarter worth approximately $30,000. 79.46% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他一些对冲基金和机构投资者最近也对该股票的持仓进行了调整。JPL Wealth Management LLC 在第三季度新购入了价值约 25,000 美元的爱德华生命科学股份。True Wealth Design LLC 在第三季度将其在爱德华生命科学的持仓增加了 251.5%。True Wealth Design LLC 目前拥有 362 股该医疗研究公司的股票，价值 28,000 美元，此前在上个季度又购买了 259 股。Hantz Financial Services Inc. 在第三季度将其在爱德华生命科学的持股增加了 76.6%。Hantz Financial Services Inc. 目前拥有 378 股该医疗研究公司的股票，价值 29,000 美元，此前在上个季度又购买了 164 股。Rakuten Securities Inc. 在第二季度将其在爱德华生命科学的持股增加了 413.7%。Rakuten Securities Inc. 目前拥有 375 股该医疗研究公司的股票，价值 29,000 美元，此前在上个季度又购买了 302 股。最后，Steigerwald Gordon &amp; Koch Inc. 在第三季度新购入了价值约 30,000 美元的爱德华生命科学股份。79.46% 的股票由机构投资者持有。</p>
</div><h2>Edwards Lifesciences Stock Up 1.2%</h2>
<div class="lb-trans"><h2>爱德华生命科学股票上涨 1.2%</h2>
</div><p>Shares of NYSE EW opened at $82.71 on Thursday. Edwards Lifesciences Corporation has a 1 year low of $65.94 and a 1 year high of $87.89. The firm's 50-day moving average is $82.16 and its 200-day moving average is $81.66. The company has a current ratio of 3.72, a quick ratio of 3.09 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $48.04 billion, a PE ratio of 45.20, a price-to-earnings-growth ratio of 2.13 and a beta of 0.93.</p>
<div class="lb-trans"><p>爱德华生命科学公司（NYSE EW）周四开盘价为 82.71 美元。爱德华生命科学公司的 1 年最低价为 65.94 美元，1 年最高价为 87.89 美元。该公司的 50 日移动平均线为 82.16 美元，200 日移动平均线为 81.66 美元。公司当前比率为 3.72，速动比率为 3.09，债务与股本比率为 0.06。该公司的市值为 480.4 亿美元，市盈率为 45.20，市盈率增长比率为 2.13，贝塔值为 0.93。</p>
</div><ul>
<li>Beyond Biotech—3 Healthcare Stocks for Growth-Minded Investors</li>
</ul>
<div class="lb-trans"><ul>
<li>超越生物技术——3 只适合成长型投资者的医疗股票</li>
</ul>
</div><p>Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing analysts' consensus estimates of $0.62 by ($0.04). Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The business had revenue of $1.57 billion for the quarter, compared to the consensus estimate of $1.54 billion. During the same period last year, the firm earned $0.59 earnings per share. The company's quarterly revenue was up 13.3% on a year-over-year basis. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Equities analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.</p>
<div class="lb-trans"><p>爱德华生命科学（NYSE:EW - 获取免费报告）最近在 2 月 10 日发布了季度财报。该医疗研究公司报告的每股收益为 0.58 美元，低于分析师一致预期的 0.62 美元，差距为 0.04 美元。爱德华生命科学的股本回报率为 14.50%，净利润率为 17.69%。该公司在本季度的收入为 15.7 亿美元，而一致预期为 15.4 亿美元。去年同期，该公司每股收益为 0.59 美元。公司的季度收入同比增长 13.3%。爱德华生命科学已将其 2026 年第一季度的指导目标设定为 0.700-0.760 每股收益。股票分析师预计爱德华生命科学公司今年将发布 2.45 每股收益。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>Several brokerages have recently commented on EW. Truist Financial set a $89.00 target price on Edwards Lifesciences and gave the stock a &#34;hold&#34; rating in a report on Wednesday, February 11th. The Goldman Sachs Group reiterated a &#34;buy&#34; rating and issued a $95.00 price objective (down from $108.00) on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. Weiss Ratings reissued a &#34;hold (c)&#34; rating on shares of Edwards Lifesciences in a research note on Wednesday, January 21st. Piper Sandler restated an &#34;overweight&#34; rating and set a $100.00 target price (up from $98.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Finally, Royal Bank Of Canada raised their target price on Edwards Lifesciences from $95.00 to $100.00 and gave the company an &#34;outperform&#34; rating in a research note on Friday, December 5th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of &#34;Moderate Buy&#34; and an average price target of $96.14.</p>
<div class="lb-trans"><p>几家券商最近对 EW 发表了评论。Truist Financial 在 2 月 11 日的报告中将爱德华生命科学的目标价设定为 89.00 美元，并给予该股票 &#34;持有&#34; 评级。高盛集团在 2 月 11 日的研究报告中重申了 &#34;买入&#34; 评级，并将爱德华生命科学的目标价下调至 95.00 美元（之前为 108.00 美元）。Weiss Ratings 在 1 月 21 日的研究报告中重新发布了爱德华生命科学的 &#34;持有 (c)&#34; 评级。Piper Sandler 在 2 月 11 日的报告中重申了 &#34;增持&#34; 评级，并将爱德华生命科学的目标价设定为 100.00 美元（之前为 98.00 美元）。最后，加拿大皇家银行在 12 月 5 日的研究报告中将爱德华生命科学的目标价从 95.00 美元上调至 100.00 美元，并给予公司 &#34;跑赢大盘&#34; 评级。三位研究分析师对该股票给予了强烈买入评级，十五位给予了买入评级，九位给予了持有评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 &#34;适度买入&#34;，平均目标价为 96.14 美元。</p>
</div><ul>
<li>3 Healthcare Pathbreakers With Long-Term Tailwinds</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只具有长期顺风的医疗行业开创者</li>
</ul>
</div><p><strong>Get Our Latest Stock Analysis on EW</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 EW 股票分析</strong></p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部交易活动</h2>
</div><p>In related news, CFO Scott B. Ullem sold 13,000 shares of the company's stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $84.92, for a total value of $1,103,960.00. Following the completion of the sale, the chief financial officer owned 39,699 shares in the company, valued at approximately $3,371,239.08. This represents a 24.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Daniel J. Lippis sold 1,019 shares of the stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $85.38, for a total value of $87,002.22. Following the completion of the transaction, the vice president directly owned 33,934 shares in the company, valued at $2,897,284.92. The trade was a 2.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 61,718 shares of company stock valued at $5,236,281 in the last 90 days. 1.29% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在相关消息中，首席财务官 Scott B. Ullem 于 3 月 11 日出售了 13,000 股公司的股票，交易价格为 84.92 美元，总价值为 1,103,960.00 美元。出售完成后，首席财务官持有公司 39,699 股，价值约为 3,371,239.08 美元。这代表了他们持股的 24.67% 的减少。该交易已在向 SEC 提交的文件中披露，可以通过此链接访问。此外，副总裁 Daniel J. Lippis 于 3 月 11 日出售了 1,019 股股票，交易价格为 85.38 美元，总价值为 87,002.22 美元。交易完成后，副总裁直接持有公司 33,934 股，价值 2,897,284.92 美元。该交易使其持股减少了 2.92%。有关此交易的更多细节可在官方 SEC 披露中找到。内部人士在过去 90 天内共出售了价值 5,236,281 美元的 61,718 股公司股票。1.29% 的股票由公司内部人士持有。</p>
</div><h2>About Edwards Lifesciences</h2>
<div class="lb-trans"><h2>关于爱德华生命科学</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.</p>
<div class="lb-trans"><p>爱德华生命科学是一家专注于结构性心脏病和重症监测产品及疗法的医疗科技公司。该公司设计、开发并制造用于外科手术和微创（经导管）程序的心脏瓣膜及相关输送系统。其产品组合涵盖多种瓣膜疾病，重点在于能够实现经导管主动脉瓣置换（TAVR）作为开放心脏手术替代方案的技术。</p>
</div><p>In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.</p>
<div class="lb-trans"><p>除了经导管心脏瓣膜——包括广为人知的 SAPIEN 系列——爱德华还提供外科组织瓣膜和心脏外科医生、介入心脏病专家及医院团队使用的辅助设备。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Edwards Lifesciences</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比爱德华生命科学更好的股票</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding EW?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 EW 感兴趣的对冲基金持有什么吗？</strong> 请访问 HoldingsChannel.com，获取爱德华生命科学公司（NYSE:EW - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVX" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=EW"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Edwards Lifesciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在爱德华生命科学吗？</h2>
</div><p>Before you consider Edwards Lifesciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑爱德华生命科学之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Edwards Lifesciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而爱德华生命科学并不在名单上。</p>
</div><p>While Edwards Lifesciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然爱德华生命科学目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Cullen Investment Group LTD. Has $744,000 Holdings in Edwards Lifesciences Corporation $EW

Market Beat

Vyome

医药突破 ETF - ALPS

爱德华生命科学

ReShape Lifesciences

纳斯达克生物科技指数 ETF - iShares Nasdaq

动态生物技术与基因组 ETF - Invesco

2 倍做多纳斯达克生物技术 ETF - ProShares

生物科技 ETF - VanEck Vectors

标普生物技术 3 倍做空 - Direxion

标普生物技术 ETF - SPDR

美国医药设备 ETF - iShares

Lifecore Biomedical

标普健康医疗设备 ETF - SPDR

Cullen Investment Group LTD. 在爱德华生命科学公司持有价值 744,000 美元的股份 $EW